<DOC>
	<DOCNO>NCT00862849</DOCNO>
	<brief_summary>Insulin lispro regular human insulin Food Drug Administration ( FDA ) -approved medication treatment diabetes mellitus . Recombinant human hyaluronidase ( rHuPH20 ) approve FDA aid absorption dispersion injectable drug . In study , rHuPH20 co-administered insulin lispro regular human insulin order determine improve absorption insulin closely mimic body 's natural increase insulin response meal .</brief_summary>
	<brief_title>Pharmacokinetic Glucodynamic Crossover Study Subcutaneously ( SC ) Administered Insulin Lispro + Recombinant Human Hyaluronidase ( rHuPH20 ) Regular Human Insulin + rHuPH20 Compared Insulin Lispro Alone</brief_title>
	<detailed_description>The purpose study compare pharmacokinetics ( absorption , distribution , breakdown elimination ) regular human insulin + recombinant human hyaluronidase ( rHuPH20 ) versus insulin lispro alone , compare pharmacokinetics insulin lispro + rHuPH20 versus insulin lispro alone . The effect regular human insulin + rHuPH20 , insulin lispro + rHuPH20 , insulin lispro alone body evaluate blood glucose measurement calculate rate glucose solution infuse maintain blood glucose within certain range . The safety tolerability insulin lispro without rHuPH20 regular human insulin rHuPH20 study . The study drug administer subcutaneous ( skin ) injection .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Healthy participant age 18 55 year , inclusive . ( Healthy define clinically relevant abnormality . ) Body mass index ( BMI ) 1827 kilogram per meter square ( kg/m^2 ) , inclusive . Total body weight &gt; 65 kilogram ( kg ) ( 143 pound [ lb ] ) men &gt; 46 kg ( 101 lb ) woman . Decision make capacity willingness comply schedule visit , treatment plan , laboratory test , study procedure include adequate venous access . Vital sign ( blood pressure , pulse rate , body temperature ) within normal range , range , assess Principal Investigator ( PI ) clinically significant ( NCS ) . Fasting blood glucose level &lt; 100 milligram per deciliter ( mg/dL ) screening . A negative serum pregnancy test ( female childbearing potential ) . Female participant childbearing potential must agree practice effective birth control abstinence currently agree continue duration time study . Signed , write Institutional Review Board ( IRB ) approve informed consent . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , oncologic , neurologic ( include history seizure ) disease ; hypoglycemic episode ; intercurrent illness ( influenza ) ; allergic disease ( include severe drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Clinical significance determine PI . As judged Investigator , clinically significant finding routine laboratory data . ( Anemia hematocrit less 33 % screen specifically exclusionary . ) Known history diabetes mellitus ( type 1 type 2 ) gestational diabetes . Known allergy hyaluronidase ingredient study drug . Positive human immunodeficiency virus ( HIV 1 ) antibody test , hepatitis B ( antihepatitis B surface antigen [ antiHBsAg ] ) hepatitis C ( antihepatitis C virus [ antiHCV ] ) antibody test . History evidence alcohol drug abuse . History evidence use tobacco nicotinecontaining product within 6 month screen screen qualitative urine nicotine test . Use drug may interfere interpretation trial result know cause clinically relevant interference insulin action glucose utilization . Donation blood excess 500 milliliter ( mL ) within 56 day dose . Participation study investigational drug device 30 day enrollment study . The participant unfit study opinion Investigator . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>rHuPH20</keyword>
	<keyword>Recombinant Human Hyaluronidase</keyword>
	<keyword>Insulin Lispro</keyword>
	<keyword>Regular Human Insulin</keyword>
</DOC>